Feb 24, 2022 / 03:15PM GMT
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior Analyst
Well, great. Thank you all for joining us at the Citi Conference here. I'm Patrick Donnelly, the Tools and Diagnostics Analyst at Citi.
Happy to have Jim Hippel, CFO of Techne; and Dave Clair from the IR team. And we can dive right in, Jim.
Questions and Answers:
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior AnalystI guess, going back a few weeks, you guys reported a pretty clean beat in your fiscal 2Q. Protein Sciences continues to be a source of strength. Maybe just at a high level, we can start with the quarter, maybe talk through kind of the moving pieces and then we can kind of dive into some more specific questions.
James T. Hippel - Bio-Techne Corporation - Executive VP of Finance & CFO
Yes. I mean it was a great quarter. It was a very strong broad-based growth quarter as it has been now for many quarters in a row for our business. As you mentioned, the Protein Science, in particular, is
Trustpilot
